Peer-reviewed veterinary case report
Changes in dog leishmaniosis antibodies after treatment
By Cantos-Barreda, Ana et al.·Published in Veterinary immunology and immunopathology·2018·University of Murcia, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Changes in serum anti-Leishmania antibody concentrations measured by time-resolved immunofluorometric assays in dogs with leishmaniosis after treatment.
- Species:
- dog
Plain-English summary
A group of 16 dogs diagnosed with leishmaniosis (a disease caused by a parasite) were treated and monitored for changes in their antibody levels over time. Blood tests showed that the levels of specific antibodies (IgG2 and IgA) decreased significantly after 30 and 180 days of treatment, indicating a positive response to the therapy. This decrease was more pronounced than what was observed with a standard test, suggesting that the new testing method could be more effective for tracking treatment progress. Overall, the dogs showed improvement, and the new testing method helped veterinarians monitor their recovery more accurately.
People also search for: dog leishmaniosis treatment · leishmania antibodies in dogs · how to treat leishmaniosis in dogs
Abstract
The aim of this study was to evaluate the changes in anti-Leishmania IgG2 and IgA antibodies measured by two time-resolved immunofluorometric assays (TR-IFMAs) recently validated and by means of a commercially available ELISA test in dogs with leishmaniosis after treatment. Serum samples from 16 dogs with clinical leishmaniosis were obtained on days 0, 30 and 180 of treatment. In addition, these serological changes were compared with the clinical signs and selected analytes (total proteins, albumin, globulins and urinary protein:creatinine ratio). Concentrations of IgG2 and IgA by TR-IFMA were significantly lower on days 30 (p < 0.05) and 180 of treatment (p < 0.0001) compared to day 0 in dogs that showed a positive response to treatment. Magnitudes of decrease of IgG2 (1.66 and 20.4-fold) and IgA (1.3 and 11.43-fold) concentrations on days 30 and 180 were greater than those of the commercially available ELISA test (1.29 and 2.06-fold), and that of other analytes (total proteins: 1.11 and 1.25-fold; globulins: 1.22 and 1.74-fold; and albumin: 0.93 and 0.8-fold). This study shows that serum IgG2 and IgA anti-Leishmania antibodies measured by TR-IFMAs were useful for treatment monitoring in dogs with leishmaniosis, showing a significant reduction in antibody concentrations earlier than the commercial ELISA assay. Results suggest that the method used for antibody measurements greatly influences the results and, consequently, the usefulness for measuring anti-Leishmania antibodies to monitor the treatment of canine leishmaniosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29571520/